clinical trial · NCT04569435
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral SclerosisANX005
brief summary
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.
started
Jan 15, 2021
primary completion
Jan 10, 2024
completion
Apr 23, 2024
last updated
Jan 6, 2025
detailed description
In this Phase 2a, multi-center, open label, proof-of-biology study, ANX005 will be administered to participants with ALS.
The study consists of approximately 22 weeks of treatment and approximately 14 weeks of follow-up. All participants will be contacted by phone 6 months after study completion.
official title
Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol